Skip to main content

Table 3 Summary of changes of all region perfusion responses by treatment and time under cold conditions

From: Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial

   Placebo Ambrisentan
Measure Change period Change (95% CI) Change P -value Overall P -value Change (95% CI) Change P -value Overall P -value
All 1 W - Base −0.13 (−0.50,0.24) 0.47 0.62 0.07 (−0.15,0.28) 0.52 0.39
  12 W - Base −0.17 (−0.54,0.20) 0.35   −0.08 (−0.30,0.14) 0.46  
  12 W - 1 W −0.04 (−0.41,0.33) 0.82   −0.15 (−0.37,0.07) 0.17  
R1 1 W - Base −0.07 (−0.40,0.25) 0.65 0.65 0.19 (−0.00,0.38) 0.054 0.036
  12 W - Base −0.15 (−0.48,0.18) 0.35   −0.06 (−0.25,0.13) 0.54  
  12 W - 1 W −0.08 (−0.41,0.25) 0.64   −0.25 (−0.44,-0.05) 0.015  
R2 1 W - Base −0.05 (−0.45,0.36) 0.81 0.79 0.07 (−0.17,0.30) 0.56 0.33
  12 W - Base −0.13 (−0.54,0.27) 0.51   −0.11 (−0.35,0.13) 0.36  
  12 W - 1 W −0.09 (−0.49,0.32) 0.67   −0.18 (−0.42,0.06) 0.14  
R3 1 W - Base −0.19 (−0.59,0.21) 0.35 0.54 0.07 (−0.16,0.30) 0.54 0.44
  12 W - Base −0.19 (−0.59,0.21) 0.33   −0.08 (−0.32,0.16) 0.50  
  12 W - 1 W −0.01 (−0.41,0.39) 0.98   −0.15 (−0.39,0.09) 0.21  
R4 1 W - Base −0.22 (−0.69,0.25) 0.36 0.57 −0.05 (−0.32,0.22) 0.70 0.84
  12 W - Base −0.21 (−0.69,0.26) 0.37   −0.08 (−0.36,0.20) 0.57  
  12 W - 1 W 0.01 (−0.47,0.48) 0.98   −0.03 (−0.31,0.25) 0.84  
Worst 1 W - Base −0.11 (−0.43,0.20) 0.47 0.41 0.18 (−0.01,0.36) 0.058 0.031
  12 W - Base −0.21 (−0.53,0.11) 0.19   −0.07 (−0.26,0.12) 0.46  
  12 W - 1 W −0.10 (−0.41,0.22) 0.54   −0.25 (−0.43,-0.06) 0.012  
  1. The ROIs are mentioned as R1 to R4 along with the area of worst perfusion, measured over the study duration. P-values are from repeated measure analysis of variance models. Base = baseline; W = week; Worst = worst perfusion. CI, confidence interval; ROI, region of interest.